Inna V. Gogunska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Inna V. Gogunska has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Diana Zabolotna
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Medical Science of Ukraine
6 shared publications - Tetyana V. Svyatenko
Dnipro State Medical University
5 shared publications - Tetyana V. Smagina
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Medical Science of Ukraine”; Kyiv, Ukraine
4 shared publications - Lilia Romaniuk
Kyiv City Clinical Hospital, Kyiv, Ukraine
3 shared publications State Institution “O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Medical Science of Ukraine”
3 shared publicationsUkraine Kyiv
3 shared publications
Latest Publications
- Open Access
- 5 January 2026
- Published by Universidade Federal de Mato Grosso do Sul in Perspectivas em Diálogo: revista de educação e sociedade
- Vol. 13 (34) , 79-100
Clinical prediction methods as a learning tool in medical education
The relevance of the study is determined by the need to develop the ability of medical students to make clinical prediction as a key component of professional thinking. The aim is to develop and evaluate the effectiveness of a training module on methods for predicting treatment outcomes in the training of future doctors. Research methods: modified Objective Structured Clinical Examination (OSCE), Clinical Reasoning Test, analytical test Medical Logic, self-assessment questionnaire, semi-structured group interview. As a result, the experimental group (EG) students (n=50) demonstrated significantly higher indicators on all criteria compared to the control group (CG) (n=50): Clinical Reasoning Test – 7.8 versus 5.1 points; OSCE – 8.3 versus 5.5; analytical thinking – 26.1 versus 19.2 points; improved self-esteem – up to +2.2 points. The training module turned out to be effective for the development of clinical reasoning, decision logic, and professional confidence. The academic novelty of the study is the first-ever approved integration of clinical prediction scales (CHA₂DS₂-VASc, SHFM, APACHE II, etc.) as a didactic tool in the Clinical Reasoning course. The prospects for future research is scaling up the module for interdisciplinary training, as well as in studying its impact on real clinical decisions of interns.
- 5 January 2026
- Published by Universidade Federal de Mato Grosso do Sul in Perspectivas em Diálogo: revista de educação e sociedade
- Vol. 13 (34) , 79-100
Open AccessClinical prediction methods as a learning tool in medical education
The relevance of the study is determined by the need to develop the ability of medical students to make clinical prediction as a key component of professional thinking. The aim is to develop and evaluate the effectiveness of a training module on methods for predicting treatment outcomes in the training of future doctors. Research methods: modified Objective Structured Clinical Examination (OSCE), Clinical Reasoning Test, analytical test Medical Logic, self-assessment questionnaire, semi-structured group interview. As a result, the experimental group (EG) students (n=50) demonstrated significantly higher indicators on all criteria compared to the control group (CG) (n=50): Clinical Reasoning Test – 7.8 versus 5.1 points; OSCE – 8.3 versus 5.5; analytical thinking – 26.1 versus 19.2 points; improved self-esteem – up to +2.2 points. The training module turned out to be effective for the development of clinical reasoning, decision logic, and professional confidence. The academic novelty of the study is the first-ever approved integration of clinical prediction scales (CHA₂DS₂-VASc, SHFM, APACHE II, etc.) as a didactic tool in the Clinical Reasoning course. The prospects for future research is scaling up the module for interdisciplinary training, as well as in studying its impact on real clinical decisions of interns.
- Open Access
- 31 December 2025
- Published by State Institution of Science "Center of Innovative Healthcare Technologies" State Administrative Department in Clinical and Preventive Medicine
- No. 8,p. 21-28
REGIONAL INCIDENCE OF ACUTE TONSILLITIS AND PERITONSILLAR ABSCESS DURING 2023–2025
Introduction. Acute tonsillitis is among the most common infectious diseases of the upper respiratory tract. Peritonsillar abscess, being the most frequent purulent complication, remains an important clinical problem in modern otorhinolaryngology. In Ukraine, studies on seasonal variations in the incidence of acute tonsillitis and peritonsillar abscess are limited, which complicates the ability to predict epidemic peaks and optimize healthcare resource allocation. Aim. To determine seasonal patterns in the incidence of acute tonsillitis and peritonsillar abscess during 2023-2025 to optimize epidemic peak forecasting and improve the organization of medical care for patients with this pathology. Materials and methods. A retrospective cohort study was conducted at the Department of Otorhinolaryngology, Bogomolets National Medical University, Kyiv, from January 2023 to September 2025. The study included patients with confirmed diagnoses of acute tonsillitis or peritonsillar abscess. Statistical analysis was performed using Python with Pearson‘s chi-square test, Kruskal-Wallis test, Mann-Kendall test, and Spearman‘s correlation analysis. Results. During the observation period, 1,014 cases of acute tonsillitis and 112 cases of peritonsillar abscess were registered. Distinct seasonal fluctuations were identified, with peaks during the winter-spring period (February-March) and minimums during summer months (July-August). The highest tonsillitis incidence was observed in February (47.0±4.4 cases per month). Mean patient age was 27.6±13.4 years for tonsillitis and 33.4±11.2 years for abscess. A strong correlation was found between tonsillitis and peritonsillar abscess incidence (r = 0.82, p < 0.001), with complications accounting for 11.0%. The seasonality coefficient was 3.62 for tonsillitis and 4.38 for abscess (p < 0.001). Stability of seasonal patterns across three years (r = 0.91-0.94, p < 0.001) suggests restoration of normal epidemiological patterns following COVID-19. Conclusions. Pronounced seasonality of acute tonsillitis and peritonsillar abscess was established, with peaks in February-March and minimums in summer. The significant relationship between both pathologies confirms the classical concept of abscess as a complication of tonsillitis. The study findings have practical implications for healthcare resource planning in the region and can be used to forecast periods of increased incidence.
- 31 December 2025
- Published by State Institution of Science "Center of Innovative Healthcare Technologies" State Administrative Department in Clinical and Preventive Medicine
- No. 8,p. 21-28
Open AccessREGIONAL INCIDENCE OF ACUTE TONSILLITIS AND PERITONSILLAR ABSCESS DURING 2023–2025
Introduction. Acute tonsillitis is among the most common infectious diseases of the upper respiratory tract. Peritonsillar abscess, being the most frequent purulent complication, remains an important clinical problem in modern otorhinolaryngology. In Ukraine, studies on seasonal variations in the incidence of acute tonsillitis and peritonsillar abscess are limited, which complicates the ability to predict epidemic peaks and optimize healthcare resource allocation. Aim. To determine seasonal patterns in the incidence of acute tonsillitis and peritonsillar abscess during 2023-2025 to optimize epidemic peak forecasting and improve the organization of medical care for patients with this pathology. Materials and methods. A retrospective cohort study was conducted at the Department of Otorhinolaryngology, Bogomolets National Medical University, Kyiv, from January 2023 to September 2025. The study included patients with confirmed diagnoses of acute tonsillitis or peritonsillar abscess. Statistical analysis was performed using Python with Pearson‘s chi-square test, Kruskal-Wallis test, Mann-Kendall test, and Spearman‘s correlation analysis. Results. During the observation period, 1,014 cases of acute tonsillitis and 112 cases of peritonsillar abscess were registered. Distinct seasonal fluctuations were identified, with peaks during the winter-spring period (February-March) and minimums during summer months (July-August). The highest tonsillitis incidence was observed in February (47.0±4.4 cases per month). Mean patient age was 27.6±13.4 years for tonsillitis and 33.4±11.2 years for abscess. A strong correlation was found between tonsillitis and peritonsillar abscess incidence (r = 0.82, p < 0.001), with complications accounting for 11.0%. The seasonality coefficient was 3.62 for tonsillitis and 4.38 for abscess (p < 0.001). Stability of seasonal patterns across three years (r = 0.91-0.94, p < 0.001) suggests restoration of normal epidemiological patterns following COVID-19. Conclusions. Pronounced seasonality of acute tonsillitis and peritonsillar abscess was established, with peaks in February-March and minimums in summer. The significant relationship between both pathologies confirms the classical concept of abscess as a complication of tonsillitis. The study findings have practical implications for healthcare resource planning in the region and can be used to forecast periods of increased incidence.
- Open Access
- 23 September 2025
- Published by Ivano-Frankivsk National Medical University in Galician Medical Journal
- Vol. 32 (4)
A Rare Clinical Association of Type I Hereditary Angioedema and Acquired Epidermolysis Bullosa: A Case Report
Introduction. Both hereditary angioedema (HAE) and acquired epidermolysis bullosa (AEB) are extremely rare disorders, and their coexistence in a single patient is unique. Awareness of this exceptional association can aid in timely diagnosis and guide safe, individualized treatment strategies. Case Report. We present a case of a 38-year-old female with co-occurring type I HAE, associated with a heterozygous SERPING1 variant c.425T>C (p.Leu142Ser) of uncertain significance previously reported in individuals with angioedema, and a rare autoimmune subepidermal blistering disorder mediated by autoantibodies against type VII collagen – AEB. Since adolescence, the patient had experienced recurrent limb edema and atypical dermatological manifestations, including macules, vesicles, and bullae, predominantly in areas exposed to mechanical stress and frequently resulting in scar formation. The disease course later progressed with an episode of acute laryngeal edema following a dental procedure. Laboratory evaluation confirmed a critically low level of C1-inhibitor and an almost complete depletion of C4 in plasma, indicating chronic activation of the classical complement pathway. Given the frequent exacerbations and severe clinical course, long-term prophylactic therapy with intravenous C1-INH (1,000 IU twice weekly) was initiated. This treatment regimen led to sustained clinical remission, resolution of angioedema episodes, notable improvement in dermatologic symptoms of AEB, and a substantial enhancement in overall quality of life. Conclusions. The coexistence of HAE and AEB is exceptionally rare, with no prior cases identified. Complement dysregulation may link these conditions, underscoring the importance of considering autoimmune blistering disorders in HAE patients with atypical skin manifestations. This case highlights a potential role for complement-targeted therapies, warranting further clinical investigation.
- 23 September 2025
- Published by Ivano-Frankivsk National Medical University in Galician Medical Journal
- Vol. 32 (4)
Open AccessA Rare Clinical Association of Type I Hereditary Angioedema and Acquired Epidermolysis Bullosa: A Case Report
Introduction. Both hereditary angioedema (HAE) and acquired epidermolysis bullosa (AEB) are extremely rare disorders, and their coexistence in a single patient is unique. Awareness of this exceptional association can aid in timely diagnosis and guide safe, individualized treatment strategies. Case Report. We present a case of a 38-year-old female with co-occurring type I HAE, associated with a heterozygous SERPING1 variant c.425T>C (p.Leu142Ser) of uncertain significance previously reported in individuals with angioedema, and a rare autoimmune subepidermal blistering disorder mediated by autoantibodies against type VII collagen – AEB. Since adolescence, the patient had experienced recurrent limb edema and atypical dermatological manifestations, including macules, vesicles, and bullae, predominantly in areas exposed to mechanical stress and frequently resulting in scar formation. The disease course later progressed with an episode of acute laryngeal edema following a dental procedure. Laboratory evaluation confirmed a critically low level of C1-inhibitor and an almost complete depletion of C4 in plasma, indicating chronic activation of the classical complement pathway. Given the frequent exacerbations and severe clinical course, long-term prophylactic therapy with intravenous C1-INH (1,000 IU twice weekly) was initiated. This treatment regimen led to sustained clinical remission, resolution of angioedema episodes, notable improvement in dermatologic symptoms of AEB, and a substantial enhancement in overall quality of life. Conclusions. The coexistence of HAE and AEB is exceptionally rare, with no prior cases identified. Complement dysregulation may link these conditions, underscoring the importance of considering autoimmune blistering disorders in HAE patients with atypical skin manifestations. This case highlights a potential role for complement-targeted therapies, warranting further clinical investigation.
- Open Access
- 30 May 2025
- Published by State Institution of Science "Center of Innovative Healthcare Technologies" State Administrative Department in Clinical and Preventive Medicine
- No. 5,p. 140-154
ASSOCIATION BETWEEN ADENOID HYPERTROPHY AND CHRONIC RHINOSINUSITIS IN CHILDREN: A SYSTEMATIC REVIEW
Introduction. Adenoid hypertrophy (AH) and chronic rhinosinusitis (CRS) are common pediatric conditions, with a prevalence of approximately 34% and 2–4%, respectively. The anatomical proximity of the pharyngeal tonsil to the nasal cavity and the similarity in clinical presentations raise questions regarding a potential association between these pathologies. Establishing correlations between adenoid hypertrophy and chronic rhinosinusitis may assist clinicians in early diagnosis and the implementation of individualized treatment approaches. Aim. To conduct a comprehensive evaluation and critical systematic analysis of existing scientific literature to determine the association between adenoid hypertrophy and chronic rhinosinusitis in children. Materials and methods. A systematic search was conducted in the PubMed/MEDLINE, Embase, Cochrane Library, Web of Science, Scopus, and Google Scholar databases covering the period from 1975 to December 2023. The search included the Keywords: “adenoid hypertrophy,” “adenoid vegetation,” “chronic rhinosinusitis,” “chronic sinusitis.” Study quality was assessed using the Newcastle-Ottawa Scale and the Cochrane Risk of Bias Tool. The review followed PRISMA guidelines. Results. A total of 41 studies were analyzed, with sample sizes ranging from 16 to 12,965 children (mean age 3.3–12.62 years). Shared etiological pathogens were identified, including Staphylococcus aureus, Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis. Biofilms were detected in 94.9% of CRS cases with AH compared to 1.9% in cases of obstructive sleep apnea syndrome (OSAS). Elevated levels of pro-inflammatory mediators (TGF-β1, sIL-2R, MMP-2, MMP-9, TIMP-1) and decreased levels of protective factors (IgA, BLIMP-1, SP-D) were reported. Impaired mucociliary clearance was demonstrated by reduced ciliary beat frequency (5.35 ± 1.06 Hz vs. 6.37 ± 0.71 Hz in controls). Adenoidectomy showed efficacy in 47–88.3% of cases in reducing CRS symptoms. Conclusions. Most studies confirm a strong association between adenoid vegetations and chronic rhinosinusitis in children, driven by common etiopathogenetic mechanisms. Adenoidectomy may be considered a first-line treatment for uncomplicated pediatric CRS. It is proposed to classify adenoid vegetations as a distinct phenotypic subtype within pediatric CRS classification.
- 30 May 2025
- Published by State Institution of Science "Center of Innovative Healthcare Technologies" State Administrative Department in Clinical and Preventive Medicine
- No. 5,p. 140-154
Open AccessASSOCIATION BETWEEN ADENOID HYPERTROPHY AND CHRONIC RHINOSINUSITIS IN CHILDREN: A SYSTEMATIC REVIEW
Introduction. Adenoid hypertrophy (AH) and chronic rhinosinusitis (CRS) are common pediatric conditions, with a prevalence of approximately 34% and 2–4%, respectively. The anatomical proximity of the pharyngeal tonsil to the nasal cavity and the similarity in clinical presentations raise questions regarding a potential association between these pathologies. Establishing correlations between adenoid hypertrophy and chronic rhinosinusitis may assist clinicians in early diagnosis and the implementation of individualized treatment approaches. Aim. To conduct a comprehensive evaluation and critical systematic analysis of existing scientific literature to determine the association between adenoid hypertrophy and chronic rhinosinusitis in children. Materials and methods. A systematic search was conducted in the PubMed/MEDLINE, Embase, Cochrane Library, Web of Science, Scopus, and Google Scholar databases covering the period from 1975 to December 2023. The search included the Keywords: “adenoid hypertrophy,” “adenoid vegetation,” “chronic rhinosinusitis,” “chronic sinusitis.” Study quality was assessed using the Newcastle-Ottawa Scale and the Cochrane Risk of Bias Tool. The review followed PRISMA guidelines. Results. A total of 41 studies were analyzed, with sample sizes ranging from 16 to 12,965 children (mean age 3.3–12.62 years). Shared etiological pathogens were identified, including Staphylococcus aureus, Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis. Biofilms were detected in 94.9% of CRS cases with AH compared to 1.9% in cases of obstructive sleep apnea syndrome (OSAS). Elevated levels of pro-inflammatory mediators (TGF-β1, sIL-2R, MMP-2, MMP-9, TIMP-1) and decreased levels of protective factors (IgA, BLIMP-1, SP-D) were reported. Impaired mucociliary clearance was demonstrated by reduced ciliary beat frequency (5.35 ± 1.06 Hz vs. 6.37 ± 0.71 Hz in controls). Adenoidectomy showed efficacy in 47–88.3% of cases in reducing CRS symptoms. Conclusions. Most studies confirm a strong association between adenoid vegetations and chronic rhinosinusitis in children, driven by common etiopathogenetic mechanisms. Adenoidectomy may be considered a first-line treatment for uncomplicated pediatric CRS. It is proposed to classify adenoid vegetations as a distinct phenotypic subtype within pediatric CRS classification.
- Open Access
- 1 January 2025
- Published by Sumy State University in Eastern Ukrainian Medical Journal
- Vol. 13 (1) , 111-121
ASSOCIATION BETWEEN THE -444C POLYMORPHISM IN THE LTC4S GENE AND COMORBIDITY RISK IN PATIENTS WITH BRONCHIAL ASTHMA
Objective: to establish associations between the polymorphic marker -444C in the LTC4S gene and the risk of developing comorbid pathology in patients with moderate bronchial asthma. Materials and Methods. For this study, we used clinical and anamnestic, anthropometric, biochemical, instrumental, medical and genetic, and statistical methods, as well as enzyme-linked immunosorbent assay. The level of asthma control was assessed using the Asthma Control Questionnaire-5 (ACQ-5). The data were analyzed using the SPSS 21.0 (IBM) statistical software and Microsoft Office Excel 2003. All participants were informed about the purpose of the study and signed written consent. Results. We examined 181 patients over 18 years with moderate persistent bronchial asthma (according to current recommendations GINA, updated 2020) with poor or no control of asthma symptoms with respiratory function limitation at < 80 % of the PEF or FEV1 reference level. The С/С genotype of the polymorphic marker -444C in the LTC4S gene was found to be associated with comorbidity risk in the subjects studied. The proportion of individuals who simultaneously have both chronic rhinosinusitis with nasal polyps and nonsteroidal anti-inflammatory drug-exacerbated respiratory disease is significantly higher among the patients with the C/C genotype (51.6%) compared to the A/A and A/C genotypes (p < 0.01). Analysis of the association between asthma and type 2 diabetes showed that patients who were carriers of the C/C genotype had a 3.75-fold increased risk of developing type 2 diabetes (OR = 3.75; 95% CI = 1.65 ÷ 8.53; p = 0.05) compared to carriers of the A/A and A/C genotypes (18% in individuals with the A/A and A/C genotypes vs. 45% in individuals with the C/C genotype). In the carriers of the C/C genotype, the risk of gastroesophageal reflux disease was 2.49 times higher (OR = 2.49; 95% CI = 1.13 ÷ 5.46; p = 0.05) compared to carriers of the A/A and A/C genotypes (30% of individuals with the A/A and А/С genotypes vs. 38.7% of individuals with the C/C genotype). The carriers of the C/C genotype had a 2.19-fold increased risk of arterial hypertension (OR = 2.19; 95% CI = 0.99÷4.84; p = 0.05) compared to carriers of the A/A and A/C genotypes (27% of individuals with the A/A and A/C genotypes vs. 45% of individuals with the C/C genotype). In the group of patients with asthma who were C/C genotype carriers, the risk of obesity increased by 2.22 times (OR (odds ratio) = 2.22; 95% CI (confidence interval) = 1.02 ÷ 4.86; p = 0.05) compared to carriers of the A/A and A/C genotypes. The prevalence of obesity in individuals with the C/C genotype was 54.4%, and in individuals with the A/A and A/C genotypes, it was 35.3%. Conclusions.The С/С genotype of the polymorphic marker -444C in the LTC4S gene is associated with a significantly higher risk of developing comorbidities: chronic rhinosinusitis with nasal polyps (3.9-fold higher risk), nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (2.8-fold higher risk), type 2 diabetes (3.8-fold higher risk), obesity (2.2-fold higher risk), gastroesophageal reflux disease (2.5-fold higher risk), and arterial hypertension (2.2-fold higher risk). Assessment of comorbidities, including genetic screening, is important for the treatment of asthma patients and for predicting the course of the disease.
- 1 January 2025
- Published by Sumy State University in Eastern Ukrainian Medical Journal
- Vol. 13 (1) , 111-121
Open AccessASSOCIATION BETWEEN THE -444C POLYMORPHISM IN THE LTC4S GENE AND COMORBIDITY RISK IN PATIENTS WITH BRONCHIAL ASTHMA
Objective: to establish associations between the polymorphic marker -444C in the LTC4S gene and the risk of developing comorbid pathology in patients with moderate bronchial asthma. Materials and Methods. For this study, we used clinical and anamnestic, anthropometric, biochemical, instrumental, medical and genetic, and statistical methods, as well as enzyme-linked immunosorbent assay. The level of asthma control was assessed using the Asthma Control Questionnaire-5 (ACQ-5). The data were analyzed using the SPSS 21.0 (IBM) statistical software and Microsoft Office Excel 2003. All participants were informed about the purpose of the study and signed written consent. Results. We examined 181 patients over 18 years with moderate persistent bronchial asthma (according to current recommendations GINA, updated 2020) with poor or no control of asthma symptoms with respiratory function limitation at < 80 % of the PEF or FEV1 reference level. The С/С genotype of the polymorphic marker -444C in the LTC4S gene was found to be associated with comorbidity risk in the subjects studied. The proportion of individuals who simultaneously have both chronic rhinosinusitis with nasal polyps and nonsteroidal anti-inflammatory drug-exacerbated respiratory disease is significantly higher among the patients with the C/C genotype (51.6%) compared to the A/A and A/C genotypes (p < 0.01). Analysis of the association between asthma and type 2 diabetes showed that patients who were carriers of the C/C genotype had a 3.75-fold increased risk of developing type 2 diabetes (OR = 3.75; 95% CI = 1.65 ÷ 8.53; p = 0.05) compared to carriers of the A/A and A/C genotypes (18% in individuals with the A/A and A/C genotypes vs. 45% in individuals with the C/C genotype). In the carriers of the C/C genotype, the risk of gastroesophageal reflux disease was 2.49 times higher (OR = 2.49; 95% CI = 1.13 ÷ 5.46; p = 0.05) compared to carriers of the A/A and A/C genotypes (30% of individuals with the A/A and А/С genotypes vs. 38.7% of individuals with the C/C genotype). The carriers of the C/C genotype had a 2.19-fold increased risk of arterial hypertension (OR = 2.19; 95% CI = 0.99÷4.84; p = 0.05) compared to carriers of the A/A and A/C genotypes (27% of individuals with the A/A and A/C genotypes vs. 45% of individuals with the C/C genotype). In the group of patients with asthma who were C/C genotype carriers, the risk of obesity increased by 2.22 times (OR (odds ratio) = 2.22; 95% CI (confidence interval) = 1.02 ÷ 4.86; p = 0.05) compared to carriers of the A/A and A/C genotypes. The prevalence of obesity in individuals with the C/C genotype was 54.4%, and in individuals with the A/A and A/C genotypes, it was 35.3%. Conclusions.The С/С genotype of the polymorphic marker -444C in the LTC4S gene is associated with a significantly higher risk of developing comorbidities: chronic rhinosinusitis with nasal polyps (3.9-fold higher risk), nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (2.8-fold higher risk), type 2 diabetes (3.8-fold higher risk), obesity (2.2-fold higher risk), gastroesophageal reflux disease (2.5-fold higher risk), and arterial hypertension (2.2-fold higher risk). Assessment of comorbidities, including genetic screening, is important for the treatment of asthma patients and for predicting the course of the disease.
- Open Access
Ukrainian Consensus on Diagnosis and Management of Vitamin D Deficiency in Adults
Vitamin D deficiency (VDD) is a global problem, however, there were no Ukrainian guidelines devoted to its screening, prevention, and treatment, which became the reason for the Consensus creation. This article aimed to present the Consensus of Ukrainian experts devoted to VDD management. Following the creation of the multidisciplinary Consensus group, consent on the formation process, drafting and fine-tuning of key recommendations, and two rounds of voting, 14 final recommendations were successfully voted upon. Despite a recent decrease in VDD prevalence in Ukraine, we recommend raising awareness regarding VDD’s importance and improving the strategies for its decline. We recommend screening the serum 25-hydroxyvitamin D (25(OH)D) level in risk groups while maintaining a target concentration of 75–125 nmol/L (30–50 ng/mL). We recommend prophylactic cholecalciferol supplementation (800–2000 IU/d for youthful healthy subjects, and 3000–5000 IU/d for subjects from the risk groups). For a VDD treatment, we recommend a short-term administration of increased doses of cholecalciferol (4000–10,000 IU/d) with 25(OH)D levels monitored after 4–12 weeks of treatment, followed by the use of maintenance doses. Additionally, we recommend assessing serum 25(OH)D levels before antiosteoporotic treatment and providing vitamin D and calcium supplementation throughout the full course of the antiosteoporotic therapy.
Open AccessUkrainian Consensus on Diagnosis and Management of Vitamin D Deficiency in Adults
Vitamin D deficiency (VDD) is a global problem, however, there were no Ukrainian guidelines devoted to its screening, prevention, and treatment, which became the reason for the Consensus creation. This article aimed to present the Consensus of Ukrainian experts devoted to VDD management. Following the creation of the multidisciplinary Consensus group, consent on the formation process, drafting and fine-tuning of key recommendations, and two rounds of voting, 14 final recommendations were successfully voted upon. Despite a recent decrease in VDD prevalence in Ukraine, we recommend raising awareness regarding VDD’s importance and improving the strategies for its decline. We recommend screening the serum 25-hydroxyvitamin D (25(OH)D) level in risk groups while maintaining a target concentration of 75–125 nmol/L (30–50 ng/mL). We recommend prophylactic cholecalciferol supplementation (800–2000 IU/d for youthful healthy subjects, and 3000–5000 IU/d for subjects from the risk groups). For a VDD treatment, we recommend a short-term administration of increased doses of cholecalciferol (4000–10,000 IU/d) with 25(OH)D levels monitored after 4–12 weeks of treatment, followed by the use of maintenance doses. Additionally, we recommend assessing serum 25(OH)D levels before antiosteoporotic treatment and providing vitamin D and calcium supplementation throughout the full course of the antiosteoporotic therapy.
- 1 January 2024
- Published by Vistka LTD in OTORHINOLARYNGOLOGY
- p. 31-44
APPLICATIONS OF MOMETASONE FUROATE AND NASAL HYPERTONIC SALINE SOLUTION WITH N-ACETYLCYSTEINE IN THE TREATMENT OF PATIENTS WITH POSTVIRAL RHINOSINUSITIS
Relevance: It has been confirmed that the use of intranasal corticosteroids improves the quality of life in patients with PVRS. Buffered hypertonic solution physiologically stimulates the surface layer of the gel, increases the hydration of the sol layer, helps to increase the thickness of the mucus layer and reduce its viscosity, resulting in an improvement of mucociliary clearance. N-acetylcysteine promotes the elimination of harmful contents from the nasal cavities and paranasal sinuses, has antibacterial properties and counteracts the formation of bacterial films, has an immunomodulatory and anti-inflammatory effect. Therefore, the complex use of mometasone furoate nasal spray and "FLU-ACIL Rhino" nasal spray (a medical product based on 3% hypertonic saline solution and 6% N-acetylcysteine) in the treatment of patients with PVRS can contribute to rapid relief of symptoms and improvement of patients' quality of life. Objective: to evaluate the efficacy and tolerability of nasal hypertonic saline solution with N-acetylcysteine and mometasone furoate in the treatment of patients with post-viral rhinosinusitis. Materials and methods: Patients with PVRS in the study were randomized into two groups of 30 people each. The standard treatment of patients in both groups included the use of intranasal corticosteroid mometasone furoate ("Nazonex") in the form of a dosed nasal spray of 200 mcg 2 times a day. Patients of the first group also received endonasal spray "FLU-ACIL rhino" – 3 spray in each nostril 3 times a day, and patients in the second group – saline isotonic nasal spray 3 times a day. The evaluation of the effectiveness of treatment in the study groups was performed on the basis of the analysis of subjective and objective symptoms of PVRS, the rate of MCC (saccharin test, before treatment and on the 10th day of treatment), the assessment of the overall severity of symptoms of PVRS in points according to the VAS scale, the assessment of the patient’s condition according to scale of Clinical Global Impressions (CGI-I), patients' assessment of tolerability of treatment. Results and discussion: The study demonstrated a more pronounced and rapid regression of objective symptoms and subjective clinical manifestations of PVRS and the average VAS score in the group of patients treated with "FLU-ACIL rhino" spray. Due to mucolytic and anti-inflammatory action of the "FLU-ACIL rhino" nasal spray, the mucociliary clearence gradually improves, which is confirmed by the results of the saccharin test. The tolerability of the complex treatment when using the nasal spray "FLU-ACIL rhino" and isotonic saline solution did not differ significantly, the cases of side effects were predictable and corresponded to a mild degree of severity, which allows us to characterize the nasal spray "FLU-ACIL rhino" as having a favorable safety profile. Conclusions: Taking into account the obtained data, the use of nasal spray "FLU-ACIL rhino" in the complex therapy of patients with PVRS can be considered as a rational choice that can contribute to a faster and more pronounced positive dynamics of PVRS symptoms and helps to improve the quality of patient’s life. Key words: postviral rhinosinusitis, mometasone furoate, N-acetylcysteine, hypertonic sodium chloride solution.
- 1 January 2024
- Published by Vistka LTD in OTORHINOLARYNGOLOGY
- p. 31-44
APPLICATIONS OF MOMETASONE FUROATE AND NASAL HYPERTONIC SALINE SOLUTION WITH N-ACETYLCYSTEINE IN THE TREATMENT OF PATIENTS WITH POSTVIRAL RHINOSINUSITIS
Relevance: It has been confirmed that the use of intranasal corticosteroids improves the quality of life in patients with PVRS. Buffered hypertonic solution physiologically stimulates the surface layer of the gel, increases the hydration of the sol layer, helps to increase the thickness of the mucus layer and reduce its viscosity, resulting in an improvement of mucociliary clearance. N-acetylcysteine promotes the elimination of harmful contents from the nasal cavities and paranasal sinuses, has antibacterial properties and counteracts the formation of bacterial films, has an immunomodulatory and anti-inflammatory effect. Therefore, the complex use of mometasone furoate nasal spray and "FLU-ACIL Rhino" nasal spray (a medical product based on 3% hypertonic saline solution and 6% N-acetylcysteine) in the treatment of patients with PVRS can contribute to rapid relief of symptoms and improvement of patients' quality of life. Objective: to evaluate the efficacy and tolerability of nasal hypertonic saline solution with N-acetylcysteine and mometasone furoate in the treatment of patients with post-viral rhinosinusitis. Materials and methods: Patients with PVRS in the study were randomized into two groups of 30 people each. The standard treatment of patients in both groups included the use of intranasal corticosteroid mometasone furoate ("Nazonex") in the form of a dosed nasal spray of 200 mcg 2 times a day. Patients of the first group also received endonasal spray "FLU-ACIL rhino" – 3 spray in each nostril 3 times a day, and patients in the second group – saline isotonic nasal spray 3 times a day. The evaluation of the effectiveness of treatment in the study groups was performed on the basis of the analysis of subjective and objective symptoms of PVRS, the rate of MCC (saccharin test, before treatment and on the 10th day of treatment), the assessment of the overall severity of symptoms of PVRS in points according to the VAS scale, the assessment of the patient’s condition according to scale of Clinical Global Impressions (CGI-I), patients' assessment of tolerability of treatment. Results and discussion: The study demonstrated a more pronounced and rapid regression of objective symptoms and subjective clinical manifestations of PVRS and the average VAS score in the group of patients treated with "FLU-ACIL rhino" spray. Due to mucolytic and anti-inflammatory action of the "FLU-ACIL rhino" nasal spray, the mucociliary clearence gradually improves, which is confirmed by the results of the saccharin test. The tolerability of the complex treatment when using the nasal spray "FLU-ACIL rhino" and isotonic saline solution did not differ significantly, the cases of side effects were predictable and corresponded to a mild degree of severity, which allows us to characterize the nasal spray "FLU-ACIL rhino" as having a favorable safety profile. Conclusions: Taking into account the obtained data, the use of nasal spray "FLU-ACIL rhino" in the complex therapy of patients with PVRS can be considered as a rational choice that can contribute to a faster and more pronounced positive dynamics of PVRS symptoms and helps to improve the quality of patient’s life. Key words: postviral rhinosinusitis, mometasone furoate, N-acetylcysteine, hypertonic sodium chloride solution.
- 1 January 2024
- Published by Vistka LTD in OTORHINOLARYNGOLOGY
- p. 32-46
Efficacy of mometasone furoate nasal spray in the treatment of patients with post-viral rhinosinusitis on the background of persistent allergic rhinitis with sensitization to house dust mites
Relevance: Acute rhinosinusitis and allergic rhinitis are widespread diseases and require adequate and effective treatment. According to the recommendations of the latest guidelines, the use of intranasal corticosteroids is recommended for the treatment of allergic rhinitis and post-viral rhinosinusitis. Since one locus morbi (nasal cavity and paranasal sinuses) is involved in the pathological process, it should be expected that the course of postviral sinusitis (PVRS) with concomitany allergic rhinitis and the efficacy of treatment of patients with this pathology may have certain peculiarities. Objective: to evaluate the efficacy of mometasone furoate nasal spray (nasonex) 200 mcg per day in the treatment of patients with post-viral rhinosinusitis (PVRS) and concomitant persistent allergic rhinitis (PAR) with sensitization to house dust mites. Materials and Methods: Adult patients with post-viral rhinosinusitis (PVRS) received mometasone furoate nasal spray (nasonex) 200 mcg per day for 15 days. The first group included patients with PVRS without accompanying allergic rhinitis (30 patients). The second group included patients with PVRS on the background of persistent allergic rhinitis (PAR) with sensitization to house dust mites (30 patients). The effectiveness of the treatment was evaluated based on the assessment of subjective and objective signs of PVRS and PAR, the assessment of the overall severity of PVRS and PAR symptoms on the VAS scale, and the assessment of the patient's condition on the scale of the general clinical condition (CGI). Results and Discussion: Nasal congestion in patients of the first group with concomitant PAR was significantly higher at the beginning of treatment. In both groups of the study, a pronounced and rapid regression of clinical manifestations of PVRS was observed, the indicators of the quality of life of the patients improved. There was a trend towards more pronounced dynamics of objective and subjective symptoms in the second group of patients, which, however, was not statistically significant. Adverse events in the study were predictable and mild in severity. Conclusions: Mometasone furoate has been well tolerated with a favorable safety profile in the treatment of patients with post-viral rhinosinusitis and concomitant persistent allergic rhinitis with sensitization to house dust mites. Keywords: mometasone furoate, post-viral rhinosinusitis, persistent allergic rhinitis.
- 1 January 2024
- Published by Vistka LTD in OTORHINOLARYNGOLOGY
- p. 32-46
Efficacy of mometasone furoate nasal spray in the treatment of patients with post-viral rhinosinusitis on the background of persistent allergic rhinitis with sensitization to house dust mites
Relevance: Acute rhinosinusitis and allergic rhinitis are widespread diseases and require adequate and effective treatment. According to the recommendations of the latest guidelines, the use of intranasal corticosteroids is recommended for the treatment of allergic rhinitis and post-viral rhinosinusitis. Since one locus morbi (nasal cavity and paranasal sinuses) is involved in the pathological process, it should be expected that the course of postviral sinusitis (PVRS) with concomitany allergic rhinitis and the efficacy of treatment of patients with this pathology may have certain peculiarities. Objective: to evaluate the efficacy of mometasone furoate nasal spray (nasonex) 200 mcg per day in the treatment of patients with post-viral rhinosinusitis (PVRS) and concomitant persistent allergic rhinitis (PAR) with sensitization to house dust mites. Materials and Methods: Adult patients with post-viral rhinosinusitis (PVRS) received mometasone furoate nasal spray (nasonex) 200 mcg per day for 15 days. The first group included patients with PVRS without accompanying allergic rhinitis (30 patients). The second group included patients with PVRS on the background of persistent allergic rhinitis (PAR) with sensitization to house dust mites (30 patients). The effectiveness of the treatment was evaluated based on the assessment of subjective and objective signs of PVRS and PAR, the assessment of the overall severity of PVRS and PAR symptoms on the VAS scale, and the assessment of the patient's condition on the scale of the general clinical condition (CGI). Results and Discussion: Nasal congestion in patients of the first group with concomitant PAR was significantly higher at the beginning of treatment. In both groups of the study, a pronounced and rapid regression of clinical manifestations of PVRS was observed, the indicators of the quality of life of the patients improved. There was a trend towards more pronounced dynamics of objective and subjective symptoms in the second group of patients, which, however, was not statistically significant. Adverse events in the study were predictable and mild in severity. Conclusions: Mometasone furoate has been well tolerated with a favorable safety profile in the treatment of patients with post-viral rhinosinusitis and concomitant persistent allergic rhinitis with sensitization to house dust mites. Keywords: mometasone furoate, post-viral rhinosinusitis, persistent allergic rhinitis.
- Open Access
- 1 January 2024
- Published by Sumy State University in Eastern Ukrainian Medical Journal
- Vol. 12 (4) , 877-885
INFLUENCE OF PREDIABETES ON CARDIOVASCULAR REMODELING INDICATORS IN HYPERTENSIVE PATIENTS WITH OBESITY
The purpose of the study was to evaluate the effect of prediabetes on cardiovascular remodeling in hypertensive patients with obesity. Materials and methods: To examine 200 patients with stage II hypertension (grade 2) and obesity (grades I-II), clinical, anamnestic, anthropometric, biochemical, and instrumental methods were employed. Among these, 60 patients had carbohydrate metabolism disorders. The degree of these disorders was assessed using fasting glycemia, impaired glucose tolerance, glycosylated hemoglobin (HbA1c), and glucose tolerance tests. Impaired fasting glycemia was established at values of glucose concentration in venous plasma ≥ 6.1 and < 7.0 mmol/l, in whole capillary blood ≥ 5.6 and < 6.1 mmol/l, and glucose index < 7.8 mmol/l both in whole capillary blood and in venous plasma during the oral glucose tolerance test. Impaired glucose tolerance was diagnosed based on fasting glucose concentrations of < 6.1 mmol/l in whole capillary blood and < 7.0 mmol/l in venous plasma, and ≥ 7.8 < 11.1 mmol/l both in whole capillary blood and in venous plasma according to the oral glucose tolerance test. The HOMA index determined insulin resistance. The data were analyzed using the statistical software SPSS 17 (IBM) and Microsoft Office Excel 2003. Results are presented as means ± standard deviation, with significance as p < 0.05 in all cases. Research results. In obese hypertensive patients with prediabetes, significantly higher values of the intima-media thickness of the common carotid artery and the carotid artery at the bifurcation level were recorded (p = 0.027 and p = 0.012 respectively), as well as a significantly higher pulse wave velocity in the carotid artery (p = 0.022). Cardiac remodeling assessment results demonstrated that patients with prediabetes had significantly larger left ventricular, left atrial, wall thickness, and left ventricular myocardial mass index, with no differences in ejection fraction values, compared to patients without prediabetes. The presence of prediabetes was characterized by a decrease in the rate of early filling of the left ventricle (p = 0.000) and the ratio of the rates of early and late filling (p = 0.000) in the absence of significant differences in the levels of the integral index of diastolic function: the ratio of the maximum speed of early diastolic flow to the maximum speed of early filling of the left ventricle (E/e'). Conclusions. Violations of carbohydrate metabolism at the stage of prediabetes in hypertensive patients with obesity contribute to the progression of vascular remodeling. They are associated with the severity of hypertrophic changes in the left ventricle. Evaluation of indicators of cardiovascular remodeling depending on the variant of prediabetes (fasting hyperglycemia and impaired glucose tolerance) did not demonstrate reliable differences in any of the indicators.
- 1 January 2024
- Published by Sumy State University in Eastern Ukrainian Medical Journal
- Vol. 12 (4) , 877-885
Open AccessINFLUENCE OF PREDIABETES ON CARDIOVASCULAR REMODELING INDICATORS IN HYPERTENSIVE PATIENTS WITH OBESITY
The purpose of the study was to evaluate the effect of prediabetes on cardiovascular remodeling in hypertensive patients with obesity. Materials and methods: To examine 200 patients with stage II hypertension (grade 2) and obesity (grades I-II), clinical, anamnestic, anthropometric, biochemical, and instrumental methods were employed. Among these, 60 patients had carbohydrate metabolism disorders. The degree of these disorders was assessed using fasting glycemia, impaired glucose tolerance, glycosylated hemoglobin (HbA1c), and glucose tolerance tests. Impaired fasting glycemia was established at values of glucose concentration in venous plasma ≥ 6.1 and < 7.0 mmol/l, in whole capillary blood ≥ 5.6 and < 6.1 mmol/l, and glucose index < 7.8 mmol/l both in whole capillary blood and in venous plasma during the oral glucose tolerance test. Impaired glucose tolerance was diagnosed based on fasting glucose concentrations of < 6.1 mmol/l in whole capillary blood and < 7.0 mmol/l in venous plasma, and ≥ 7.8 < 11.1 mmol/l both in whole capillary blood and in venous plasma according to the oral glucose tolerance test. The HOMA index determined insulin resistance. The data were analyzed using the statistical software SPSS 17 (IBM) and Microsoft Office Excel 2003. Results are presented as means ± standard deviation, with significance as p < 0.05 in all cases. Research results. In obese hypertensive patients with prediabetes, significantly higher values of the intima-media thickness of the common carotid artery and the carotid artery at the bifurcation level were recorded (p = 0.027 and p = 0.012 respectively), as well as a significantly higher pulse wave velocity in the carotid artery (p = 0.022). Cardiac remodeling assessment results demonstrated that patients with prediabetes had significantly larger left ventricular, left atrial, wall thickness, and left ventricular myocardial mass index, with no differences in ejection fraction values, compared to patients without prediabetes. The presence of prediabetes was characterized by a decrease in the rate of early filling of the left ventricle (p = 0.000) and the ratio of the rates of early and late filling (p = 0.000) in the absence of significant differences in the levels of the integral index of diastolic function: the ratio of the maximum speed of early diastolic flow to the maximum speed of early filling of the left ventricle (E/e'). Conclusions. Violations of carbohydrate metabolism at the stage of prediabetes in hypertensive patients with obesity contribute to the progression of vascular remodeling. They are associated with the severity of hypertrophic changes in the left ventricle. Evaluation of indicators of cardiovascular remodeling depending on the variant of prediabetes (fasting hyperglycemia and impaired glucose tolerance) did not demonstrate reliable differences in any of the indicators.
- 1 July 2023
- Published by Khazar University Press in Khazar Journal of Humanities and Social Sciences
- Vol. 26 (3) , 21-27
Functioning of Healthcare Facilities under the Martial Law
- 1 July 2023
- Published by Khazar University Press in Khazar Journal of Humanities and Social Sciences
- Vol. 26 (3) , 21-27
Functioning of Healthcare Facilities under the Martial Law